Yann Bertolani, Albert Arnaiz-Camacho, Jorge Fernández-Engroba, Jose García-Arumí, Miguel-Ángel Zapata
{"title":"Successful use of PRGF-endoret® and ILM peeling for full thickness macular hole in MacTel type 2: A case report and review of literature.","authors":"Yann Bertolani, Albert Arnaiz-Camacho, Jorge Fernández-Engroba, Jose García-Arumí, Miguel-Ángel Zapata","doi":"10.1177/11206721241301933","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole in Macular Telangiectasia type 2.</p><p><strong>Case presentation: </strong>A case report of a full thickness macular hole (FTMH) associated with Macular Telangiectasia (MacTel) type 2 is described. 25-G vitrectomy with internal limiting membrane (ILM) peeling and use of (PRGF-Endoret®) was performed. Several ophthalmological visits were conducted and multiple diagnostic tests were carried out including optical coherence tomography (OCT) and fluorescein angiography. A 72-year-old man under follow-up for MacTel type 2 presented with worsening vision in his left eye, with a best visual corrected acuity (BVCA) of 20/80. OCT demonstrated a FTMH in the left eye measuring 264 µm. A 25-gauge pars plana vitrectomy surgery was performed with ILM peeling, use of PRGF-Endoret® and tamponade with 20% sulfur hexafluoride (SF6). Three weeks after surgery, complete anatomical closure was observed with a BVCA of 20/40, which improved to 20/25 one year after the surgery.</p><p><strong>Conclusions: </strong>The use of PRGF associated with ILM peeling may be a useful tool in the treatment of macular holes associated with MacTel Type 2 with excellent anatomical and functional outcomes.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721241301933"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721241301933","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: To describe the successful use of plasma rich in growth factors (PRGF-Endoret®) and internal limiting membrane peeling for full thickness macular hole in Macular Telangiectasia type 2.
Case presentation: A case report of a full thickness macular hole (FTMH) associated with Macular Telangiectasia (MacTel) type 2 is described. 25-G vitrectomy with internal limiting membrane (ILM) peeling and use of (PRGF-Endoret®) was performed. Several ophthalmological visits were conducted and multiple diagnostic tests were carried out including optical coherence tomography (OCT) and fluorescein angiography. A 72-year-old man under follow-up for MacTel type 2 presented with worsening vision in his left eye, with a best visual corrected acuity (BVCA) of 20/80. OCT demonstrated a FTMH in the left eye measuring 264 µm. A 25-gauge pars plana vitrectomy surgery was performed with ILM peeling, use of PRGF-Endoret® and tamponade with 20% sulfur hexafluoride (SF6). Three weeks after surgery, complete anatomical closure was observed with a BVCA of 20/40, which improved to 20/25 one year after the surgery.
Conclusions: The use of PRGF associated with ILM peeling may be a useful tool in the treatment of macular holes associated with MacTel Type 2 with excellent anatomical and functional outcomes.
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.